Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins sits in the top decile of US sponsors by registered trial count (#69 of 15,742 sponsors by registered trial count).
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins: 523 sponsored US clinical trials, 69 recruiting.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins sponsors 523 registered US clinical trials on ClinicalTrials.gov, 69 of them currently recruiting, and 301 completed. 5 of these trials are in Phase 3-4 (later-stage) and 395 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Prostate Cancer, with 17 trials.
Top-decile sponsor footprint
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins ranks in the top decile of sponsors by registered trial count (#69 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
301 of 415 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (72.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
523 total, page 8 of 11
A Study of Dasatinib, Cetuximab and Radiation With or Without Cisplatin in HNSCC
NCT00882583
Trial of High Dose Lenalidomide in Patients With MDS and AML With Trilineage Dysplasia
NCT00867308
Concentration and Activity of Lapatinib in Vestibular Schwannomas
NCT00863122
Allo BMT Using Matched Related/Unrelated Donors With FluBu and HiCY
NCT00809276
Topical Application of Sulforaphane-containing Broccoli Sprout Extracts on Radiation Dermatitis
NCT00894712
Study to Evaluate the Effect of Sulforaphane in Broccoli Sprout Extract on Breast Tissue
NCT00982319
Ipilimumab +/- Vaccine Therapy in Treating Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer
NCT00836407
R-ICE and High-Dose Cyclophosphamide With PET/CT for Diffuse Large B-Cell Non-Hodgkin's Lymphoma
NCT00809341
Hypofractionated Adaptive Image-Guided Radiation Therapy for Localized Adenocarcinoma of the Prostate
NCT00809991
Safety Study of Bone Marrow Transplant Using Mismatched Tissue Followed by Chemotherapy
NCT00796562
Trastuzumab, Cyclophosphamide, and Vaccine Therapy in Treating Patients With High-Risk or Metastatic Breast Cancer
NCT00847171
Vaccine Therapy With or Without Imiquimod in Treating Patients With Grade 3 Cervical Intraepithelial Neoplasia
NCT00788164
Phase II Study of Itraconazole and Pemetrexed in Patients With Previously Treated Non-Squamous NSCLC
NCT00769600
Phase II Study of Doxorubicin and Avastin® in Sarcoma.
NCT00755261
Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Undergoing Chemotherapy and Radiation Therapy for Stage I or Stage II Pancreatic Cancer That Can Be Removed by Surgery
NCT00727441
Non-Myeloablative Bone Marrow Transplant for Patients With Sickle Cell Anemia and Other Blood Disorders
NCT00489281
Screening for Early Pancreatic Neoplasia (Cancer of the Pancreas Screening or CAPS4 Study)
NCT00714701
Magnetic Acupressure in Reducing Pain in Cancer Patients Undergoing Bone Marrow Aspiration and Biopsy
NCT00670917
Valproic Acid in Treating Patients With Progressive, Non-Metastatic Prostate Cancer
NCT00670046
Trial of Partial Breast Irradiation With Various Concurrent Chemotherapy Regimens
NCT00681993
Study of Colon GVAX and Cyclophosphamide in Patients With Metastatic Colorectal Cancer
NCT00656123
Standard Pain Control or Intrathecal Therapy in Controlling Pain in Patients With Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer
NCT00660348
Testosterone Gel in Preventing Weakness Caused by Steroid Therapy in Men With Glioma
NCT00631137
Transplantation of Umbilical Cord Blood Following Chemotherapy for Blood Cancers
NCT00539656
Activated White Blood Cells With ASCT for Newly Diagnosed Multiple Myeloma
NCT00566098
Hydroxychloroquine, Radiation, and Temozolomide Treating Patients With Newly Diagnosed Glioblastoma Multiforme
NCT00486603
Studying Fentanyl in Patients With Cancer
NCT00899951
Interferon Alfa and Interleukin-6 in Treating Patients With Recurrent Multiple Myeloma
NCT00470093
Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Children With Relapsed or Refractory Acute Leukemias
NCT00852709
Assessment of Liver Cancer Response to TACE Using MultiHance-Enhanced MRI.
NCT00539253
Freehand Ultrasound Elasticity Imaging in Liver Surgery
NCT00942383
Vaccine Therapy in Treating Patients With Myelodysplastic Syndromes
NCT00361296
Ultrasound Based Localization of Lumpectomy Bed in Anatomical Coordinate System
NCT00681304
Identifying Circulating Breast Cancer Cells in Women With Metastatic Breast Cancer
NCT00897338
Safety and Efficacy Study of I-131 Tositumomab in Patients With Relapsed/Refractory Hodgkin's Lymphoma
NCT00484874
Cyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial Cancer
NCT00499733
A Trial of Tadalafil in Patients With Squamous Cell Carcinoma of the Upper Aero Digestive Tract
NCT00894413
Musculoskeletal Outcomes After Bone Marrow Transplant
NCT00558948
Cetuximab in Treating Patients With Precancerous Lesions of the Upper Aerodigestive Tract
NCT00524017
High-Dose Cyclophosphamide for Steroid Refractory GVHD
NCT00492921
Safety Study to Determine the Appropriate Dose of Antibody Against Tumor Cells to Best Target Patients With Pancreatic Cancer.
NCT00364364
Vaccine Therapy With or Without Donor Lymphocyte Infusion in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Multiple Myeloma Undergoing Donor Stem Cell Transplant
NCT00469820
Vaccine Therapy in Treating Patients Who Have Received First-Line Therapy for Hodgkin's Lymphoma
NCT00478062
Gossypol (AT-101) and Temozolomide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
NCT00390403
Making Decisions About Participating in a Cancer Clinical Trial for Patients With Stage II, Stage III, or Stage IV Pancreatic Cancer or Stage III or Stage IV Colon Cancer or Rectal Cancer
NCT00478010
Tetra-O-Methyl Nordihydroguaiaretic Acid in Treating Patients With Recurrent High-Grade Glioma
NCT00404248
Lenalidomide and Vaccine Therapy in Treating Patients With Relapsed or Refractory Multiple Myeloma
NCT00445484
DNA in Predicting Response After Systemic Therapy in Women With Metastatic Breast Cancer
NCT00899548
Pattern of Cell Death Following Neoadjuvant Therapy for Metastatic Colon Cancer
NCT00414492
Pharmacokinetics in Patients With Newly Diagnosed High-Grade Glioma Receiving Temozolomide and Radiation Therapy
NCT00471653
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 185 |
| Phase 2 | 210 |
| Phase 3 | 5 |
Therapeutic Areas
What is open in the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins pipeline
69 recruiting of 523 indexed (13% open); 301 completed (58%).
Phase mix: 5 late (III/IV) vs 395 early (I/II) (early-phase heavy).
Top condition: Prostate Cancer (17 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins: open-pipeline peers nationwide
Peers matched on 523 registered trials and 13% open enrollment, not the therapeutic-area sidebar.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 523 trials (± recruiting share)
- AbbVie · 526 trials · 21% recruiting
- Boehringer Ingelheim · 515 trials · 8% recruiting
- Gilead Sciences · 504 trials · 5% recruiting
- H. Lee Moffitt Cancer Center and Research Institute · 502 trials · 16% recruiting
Sponsors near 13% open enrollment (± trial volume)
- MetroHealth Medical Center · 13% recruiting · 76 trials
- Texas Tech University Health Sciences Center · 13% recruiting · 76 trials
- Chiesi Farmaceutici S.p.A. · 13% recruiting · 30 trials
- Dizal Pharmaceuticals · 13% recruiting · 15 trials
Related
What to do with this Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins page
523 registered trials is a research-attention snapshot, not an endorsement of Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins or any single study.
- 69 of Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Prostate Cancer is the condition Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Prostate Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins pipeline card: 523 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.